Magnetar Financial LLC Makes New $324,000 Investment in USANA Health Sciences, Inc. $USNA

Key Points

• Magnetar Financial LLC acquired a new stake in USANA Health Sciences, purchasing 12,023 shares for approximately $324,000, representing about 0.06% of the company's stock.
• USANA reported quarterly earnings of $0.74 per share, exceeding analyst estimates of $0.54, with revenue of $235.85 million compared to expectations of $225.20 million.
• Insider trading activity showed a significant sale by David Mulham, who sold 3,515 shares at an average price of $30.26, indicating a 27.51% decrease in his holdings.

Magnetar Financial LLC acquired a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,023 shares of the company's stock, valued at approximately $324,000. Magnetar Financial LLC owned approximately 0.06% of USANA Health Sciences at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. US Bancorp DE increased its holdings in shares of USANA Health Sciences by 13.1% during the first quarter. US Bancorp DE now owns 4,611 shares of the company's stock worth $124,000 after buying an additional 535 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of USANA Health Sciences by 7.1% in the first quarter. Exchange Traded Concepts LLC now owns 9,184 shares of the company's stock valued at $248,000 after purchasing an additional 606 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of USANA Health Sciences by 339.6% in the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock valued at $27,000 after purchasing an additional 771 shares in the last quarter. Martingale Asset Management L P increased its holdings in shares of USANA Health Sciences by 5.4% in the first quarter. Martingale Asset Management L P now owns 17,542 shares of the company's stock valued at $473,000 after purchasing an additional 900 shares in the last quarter. Finally, Versant Capital Management Inc increased its holdings in shares of USANA Health Sciences by 542.5% in the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock valued at $31,000 after purchasing an additional 971 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company's stock.

USANA Health Sciences Price Performance

Shares of NYSE USNA traded up $0.01 during midday trading on Friday, reaching $31.78. 234,152 shares of the stock were exchanged, compared to its average volume of 90,734. The company has a market capitalization of $580.58 million, a price-to-earnings ratio of 17.65, a P/E/G ratio of 1.01 and a beta of 0.64. USANA Health Sciences, Inc. has a 12 month low of $23.10 and a 12 month high of $41.83. The business has a 50-day simple moving average of $31.24 and a two-hundred day simple moving average of $29.60.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.54 by $0.20. The business had revenue of $235.85 million for the quarter, compared to analysts' expectations of $225.20 million. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. Equities research analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 1,058 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total value of $30,787.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Mulham Mulham sold 3,515 shares of the business's stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the sale, the insider directly owned 9,260 shares in the company, valued at $280,207.60. This represents a 27.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,073 shares of company stock worth $151,982 over the last ninety days. 0.63% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, USANA Health Sciences has a consensus rating of "Hold" and an average target price of $36.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.